Proteomics International Laboratories' (ASX:PIQ) OxiDx subsidiary obtained a new Australian patent for the OxiDx oxidative stress diagnostic test, according to a Friday filing with the Australian bourse.
OxiDx was designed to detect oxidative stress through a finger-prick blood sample.
The second-generation patent, valid until March 2039, follows similar patents in Europe and Japan. The company's original OxiDx patents cover Australia and the US and are valid until 2026 and 2028, respectively, per the filing.
The second-generation patent is pending in the US, Singapore, India, and China, the filing added.
The diagnostics company's shares were up 4% in recent Friday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.